UBS Group AG Lowers Position in Compass Pathways PLC Sponsored ADR $CMPS

UBS Group AG reduced its stake in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 4.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,038,444 shares of the company’s stock after selling 105,966 shares during the quarter. UBS Group AG’s holdings in Compass Pathways were worth $14,065,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Advisory Services Network LLC purchased a new stake in Compass Pathways in the 3rd quarter valued at $41,000. BIT Capital GmbH purchased a new stake in Compass Pathways in the 3rd quarter valued at $54,000. Raymond James Financial Inc. raised its position in Compass Pathways by 82.7% in the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock valued at $79,000 after buying an additional 6,228 shares during the last quarter. U.S. Capital Wealth Advisors LLC purchased a new stake in Compass Pathways in the 4th quarter valued at $104,000. Finally, CWM LLC raised its position in Compass Pathways by 19.2% in the 3rd quarter. CWM LLC now owns 15,650 shares of the company’s stock valued at $90,000 after buying an additional 2,525 shares during the last quarter. 46.19% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on CMPS shares. Lifesci Capital raised Compass Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of Compass Pathways in a research report on Tuesday, April 28th. B. Riley Financial started coverage on Compass Pathways in a research report on Friday, April 24th. They issued a “buy” rating and a $17.00 price target for the company. Royal Bank Of Canada increased their price target on Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. Finally, UBS Group set a $18.00 price target on Compass Pathways in a research report on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Compass Pathways presently has an average rating of “Moderate Buy” and a consensus target price of $20.55.

Compass Pathways Stock Up 17.0%

Shares of NASDAQ:CMPS opened at $10.96 on Thursday. The company has a market capitalization of $1.41 billion, a PE ratio of -3.55 and a beta of 2.39. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.77 and a quick ratio of 0.77. The business has a fifty day moving average price of $7.09 and a two-hundred day moving average price of $6.69. Compass Pathways PLC Sponsored ADR has a 1 year low of $2.25 and a 1 year high of $11.08.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Analysts forecast that Compass Pathways PLC Sponsored ADR will post -1.83 earnings per share for the current year.

Compass Pathways Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.